Parkinson's Disease is among the most common neurodegenerative diseases in the contemporary world. Recent years have witnessed increasing intensification of development of therapies for the disease. Particularly notable are the therapies based on targeting the α-synuclein neurotoxic protein. The present study aims to provide a snapshot of the status quo of developing two such therapies, namely buntanetap tartrate and prasinezumab. The study adopts the literature review research methodology. Topics discussed in the study include the following: overview of Parkinson's Disease; types of therapies for Parkinson's Disease; status quo of therapy development for Parkinson's Disease; research on buntanetap tartrate as a treatment to Parkinson's Disease; research on prasinezumab as a therapy for Parkinson's Disease; potential effectiveness of buntanetap and prasinezumab as treatments for Parkinson's Disease; criticism and doubts surrounding the use of buntanetap and prasinezumab as therapies for Parkinson's Disease. Discussions in this study show that buntanetap and prasinezumab are being actively tested in order to confirm their effectiveness in halting the progression of Parkinson's Disease. However, trial studies conducted for testing the therapies thus far have presented inconclusive findings. Therefore, further research is needed for arriving at better understanding of the extent to which buntanetap and prasinezumab are potential therapies for controlling Parkinson's Disease.

Keywords: Parkinson's Disease, buntanetap, prasinezumab, α-synuclein, neurodegenerative diseases.